Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base

Formation and regional foundations

Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base appears in authority public-notice material dated 2024, and each named entity uses its corresponding public record.

The authority public-notice material uses the name Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base. A working review can begin with candidate compounds and drug screening.

Core geography: China Heart Valley area in Mentougou

Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base operating-chain map

Six supply-and-demand connections in Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base

The six nodes run from candidate compounds to cardiovascular medicines delivery arrangements, then return delivery feedback to drug screening.

• candidate compounds — Input review for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base centres on candidate compounds and checks material identity, compliance documents, lot and storage or transport conditions before work begins.
• drug screening — Operations for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base follow drug screening and record controlled steps, validation status, environmental conditions and deviation handling at each handoff.
• cardiovascular drug candidates — Output scope for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base covers cardiovascular drug candidates, with intended scope, test results, release documents and storage or transport requirements defined separately.
• medical institutions — Demand for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base comes from medical institutions, with specifications and delivery terms checked against research, production, clinical or regulatory use conditions.
• cardiovascular medicines acceptance criteria — Acceptance for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base follows cardiovascular medicines acceptance criteria, with measurement and retest results linked to a controlled lot or validated revision.
• cardiovascular medicines delivery arrangements — Delivery for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base follows cardiovascular medicines delivery arrangements and checks release status, temperature control, protection, handover and traceability files.

01 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Inputs and inbound terms

This chapter reviews input mix and inbound conditions for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Input mix: candidate compounds, biomaterials, precision parts, clinical needs and testing standards.

For the path from candidate compounds through drug screening to cardiovascular drug candidates, first check material identity, compliance documents, lot and storage or transport conditions, retain practical samples and verify sites, equipment or services through records and field conditions.

In Beijing, physical inputs such as candidate compounds carry a lot trail through packaging, transport and traceability records, while sites, equipment or services retain their own reference numbers.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, material identity, compliance documents, lot and storage or transport conditions should be explicit.

02 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Operations and handoffs

This chapter reviews production stages and engineering interfaces for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Operating sequence: drug screening, device design, prototyping, performance assessment and registration validation.

After a change to drug screening, reassess cardiovascular medicines acceptance criteria and update records for controlled steps, validation status, environmental conditions and deviation handling.

Before drug screening in Beijing moves to cardiovascular drug candidates, use a limited trial, test harvest or stage result to confirm the output boundary.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, equipment, software versions and accountable owners should be explicit.

03 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Outputs and acceptance

This chapter reviews output forms and acceptance measures for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Output range: cardiovascular drug candidates, interventional products, testing dossiers and commercialization services.

Acceptance of cardiovascular drug candidates from drug screening in Beijing should specify reproducible samples, methods, environments and decision rules.

Review of cardiovascular drug candidates separately covers registration or filing boundaries, specifications, lot records, storage and transport conditions, and user support.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, specifications, test environments and delivery documents should be explicit.

04 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Demand and purchasing

This chapter reviews demand side and purchasing routes for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Demand side: medical institutions, pharmaceutical firms, device distributors and research rightsholders.

In Beijing, demand from medical institutions can be separated by research, production, clinical or regulatory use conditions, then matched to the conditions for cardiovascular drug candidates.

An inquiry from medical institutions for cardiovascular drug candidates should state acceptance and delivery terms as well as volume and price.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, use case, volume range and acceptance owner should be explicit.

05 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Named entities

The three named entities for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base each link to their own public material.

Beijing Baiyang Chengchuang Pharmaceutical R&D Co., Ltd: The company applied for the Baiyang cardiovascular base under its former name, an exchange disclosure confirms its current R&D company name.

Beijing Baiyang Zhixin Medical Research Co., Ltd: The municipal plan lists its cardiovascular medical-research platform project.

Beijing Baiyang Guoxin Medical Technology Co., Ltd: The municipal plan lists its medical-technology development and commercialization project.

• The three named entities for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base use only relationships directly stated in their own material.

06 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Quality and records

This chapter reviews quality review and technical files for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Review development records, biocompatibility, performance tests, clinical plans and registration status.

When operating conditions for drug screening in Beijing change, reassess cardiovascular medicines acceptance criteria and update controlled steps, validation status, environmental conditions and deviation handling.

After release of cardiovascular drug candidates from drug screening in Beijing, set retesting, exception isolation and correction deadlines so responsibility remains traceable to a controlled lot or validated revision.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, samples, test conditions and decision rules should be explicit.

07 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Delivery and site handover

This chapter reviews transport, delivery and site handover for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Samples move under temperature or sterile controls, while test records transfer through controlled systems.

When delivery of cardiovascular drug candidates from drug screening in Beijing spans several traceable units or service stages, every deliverable should link back to its record.

Delivery of cardiovascular drug candidates to medical institutions keeps packaging integrity, lot labels, storage temperature, transit time and arrival checks linked.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, packaging, temperature, humidity, shock protection and arrival checks should be explicit.

08 · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base: Engagement and due diligence

This chapter reviews engagement sequence and due-diligence list for Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base.

Before project launch, verify patent boundaries, testing credentials, registration routes, scale-up conditions and adverse-event duties.

When checking entities including Beijing Baiyang Chengchuang Pharmaceutical R&D Co., Ltd, cluster designation does not prove performance; before quoting cardiovascular drug candidates, assign responsibility for cardiovascular medicines acceptance criteria and cardiovascular medicines delivery arrangements.

In China Heart Valley area in Mentougou, an engagement for cardiovascular drug candidates from drug screening can begin with a small lot, pilot or stage deliverable before capacity, lead time and longer arrangements are set.

• Before Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base moves into execution, separate conclusions on regional designation and company capability should be explicit.

Sources and reading notes

Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base follows the name used in the authority public-notice material, records the three companies only by complete legal name and directly stated relationship, and leaves capacity, pricing and engagement terms for separate checks.

• Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base is the cluster name used in the 2024 authority public-notice material.
• The corresponding public record states this relationship for Beijing Baiyang Chengchuang Pharmaceutical R&D Co., Ltd: Mentougou | The company applied for the Baiyang cardiovascular base under its former name, an exchange disclosure confirms its current R&D company name.
• The corresponding public record states this relationship for Beijing Baiyang Zhixin Medical Research Co., Ltd: Mentougou | The municipal plan lists its cardiovascular medical-research platform project.
• The corresponding public record states this relationship for Beijing Baiyang Guoxin Medical Technology Co., Ltd: Mentougou | The municipal plan lists its medical-technology development and commercialization project.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

• Beijing Baiyang Chengchuang Pharmaceutical R&D Co., Ltd. — Beijing Baiyang Chengchuang Pharmaceutical R&D Co., Ltd. · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base · Source: Qingdao Baheal Medical notice on its controlling shareholder's capital increase and proposed ownership change
• Beijing Baiyang Guoxin Medical Technology Co., Ltd. — Beijing Baiyang Guoxin Medical Technology Co., Ltd. · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base · Source: Beijing economic and social plan implementation report for 2025 and plan for 2026
• Beijing Baiyang Zhixin Medical Research Co., Ltd. — Beijing Baiyang Zhixin Medical Research Co., Ltd. · Baiyang Cardiovascular Innovative Medicines and Devices Incubation Base · Source: Beijing economic and social plan implementation report for 2025 and plan for 2026
• Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.

• Publicity notice for the first Beijing future-industry incubation bases — Beijing Municipal Bureau of Economy and Information Technology
• Mentougou builds China Heart Valley — Beijing Municipal Science and Technology Commission
• Mentougou concentrates specialist resources for China Heart Valley — Beijing Municipal Science and Technology Commission
• Beijing economic and social plan implementation report for 2025 and plan for 2026 — Beijing Municipal Development and Reform Commission
• China Heart Congress innovation forum and Jingxi medicine-device conference — Beijing Municipal Science and Technology Commission
• Beijing 2024 plan implementation and 2025 development plan — Beijing Municipal Commerce Bureau
• First creation list of Beijing future-industry incubation bases — Beijing Municipal Bureau of Economy and Information Technology
• Qingdao Baheal Medical notice on its controlling shareholder's capital increase and proposed ownership change — Shenzhen Stock Exchange Disclosure Platform